{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:44:29Z","timestamp":1794368669175,"version":"4.9.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Presbyopia is a common progressive vision disorder characterised by an inability to focus on near objects. The emergence of newer treatment options in addition to spectacles or contact lenses highlights the importance of assessing patient\/user preferences.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>People with presbyopia and healthcare professionals (HCPs) took part in a moderated, structured discussion of specific questions on a virtual advisory-board platform. The objective was to better understand unmet needs and the experience of living with the condition. Closed and open questions were included.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Nine individuals (age 40 to 70\u00a0years) with presbyopia participated, from Australia, China, France, Italy, Ireland, Japan and the US. One ophthalmologist and one optometrist represented the perspective of HCPs. Over two weeks, 621 posts were entered on the platform. There was widespread agreement that the often stated association between age and presbyopia was unfortunate. Some participants had developed presbyopia at 30\u201345\u00a0years of age. What is more, the association with age was seen as implying a natural process, reducing the incentive to treat. Instead there was a call for an action-oriented view of presbyopia as a condition which may be effectively treated in the future. All participants experienced dealing with presbyopia as burdensome, affecting quality of life to varying degrees. When considering new treatments, convenience was the most important factor. The option to administer drops when needed was considered favourable, but short-acting treatments may not reduce inconvenience compared with spectacles. Participants viewed a therapy that targets the underlying cause of the condition favourably compared with symptomatic treatment. Side effects would severely reduce the appeal of drops. For clinical trials in presbyopia, patient-reported outcomes should be mandatory and need adequately to capture quality of life. Studies in presbyopia must be designed to minimise the inconvenience to participants in order to counter the risk of high drop-out rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The interactive format provided insights into living with presbyopia, particularly the negative impact on quality of life, subjects\u2019 openness to new therapies, and the need to move away from considering the condition an unavoidable and intractable consequence of ageing.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-022-02432-9","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T13:04:39Z","timestamp":1651755879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Living with presbyopia: experiences from a virtual roundtable dialogue among impacted individuals and healthcare professionals"],"prefix":"10.1186","volume":"22","author":[{"given":"Mile","family":"Brujic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wuttke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ali\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"2432_CR1","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1167\/iovs.15-18413","volume":"57","author":"WH Garner","year":"2016","unstructured":"Garner WH, Garner MH. Protein Disulfide Levels and Lens Elasticity Modulation: Applications for Presbyopia. Investig Opthalmology Vis Sci. 2016;57:2851.","journal-title":"Investig Opthalmology Vis Sci"},{"key":"2432_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1080\/10255842.2016.1228907","volume":"20","author":"G David","year":"2017","unstructured":"David G, Pedrigi RM, Humphrey JD. Accommodation of the human lens capsule using a finite element model based on nonlinear regionally anisotropic biomembranes. Comput Methods Biomech Biomed Engin. 2017;20:302\u20137.","journal-title":"Comput Methods Biomech Biomed Engin"},{"key":"2432_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000060809","volume":"35","author":"DH Sliney","year":"2002","unstructured":"Sliney DH. Geometrical gradients in the distribution of temperature and absorbed ultraviolet radiation in ocular tissues. Dev Ophthalmol. 2002;35:40\u201359.","journal-title":"Dev Ophthalmol"},{"key":"2432_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0039-6257(03)00086-9","volume":"48","author":"RA Weale","year":"2003","unstructured":"Weale RA. Epidemiology of refractive errors and presbyopia. Surv Ophthalmol. 2003;48:515\u201343.","journal-title":"Surv Ophthalmol"},{"key":"2432_CR5","first-page":"660","volume":"60","author":"MA Stevens","year":"1989","unstructured":"Stevens MA, Bergmanson JP. Does sunlight cause premature aging of the crystalline lens? J Am Optom Assoc. 1989;60:660\u20133.","journal-title":"J Am Optom Assoc"},{"key":"2432_CR6","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.ophtha.2018.04.013","volume":"125","author":"TR Fricke","year":"2018","unstructured":"Fricke TR, Tahhan N, Resnikoff S, Papas E, Burnett A, Ho SM, et al. Global prevalence of presbyopia and vision impairment from uncorrected presbyopia. Ophthalmology. 2018;125:1492\u20139.","journal-title":"Ophthalmology"},{"key":"2432_CR7","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ophtha.2006.01.028","volume":"113","author":"I Patel","year":"2006","unstructured":"Patel I, Munoz B, Burke AG, Kayongoya A, Mchiwa W, Schwarzwalder AW, et al. Impact of presbyopia on quality of life in a rural African setting. Ophthalmology. 2006;113:728\u201334.","journal-title":"Ophthalmology"},{"key":"2432_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.oftal.2020.07.012","volume":"96","author":"R Bilbao-Calabuig","year":"2021","unstructured":"Bilbao-Calabuig R, G\u00f3nzalez-L\u00f3pez F, Llovet-Rausell A, Ortega-Usobiaga J, Tejerina Fern\u00e1ndez V, Llovet-Osuna F. Lens-based surgical correction of presbyopia. Where are we in 2020? Arch Soc Espanola Oftalmol. 2021;96:74\u201388.","journal-title":"Arch Soc Espanola Oftalmol."},{"key":"2432_CR9","doi-asserted-by":"publisher","DOI":"10.2196\/18306","volume":"22","author":"JS Wolffsohn","year":"2020","unstructured":"Wolffsohn JS, Leteneux-Pantais C, Chiva-Razavi S, Bentley S, Johnson C, Findley A, et al. Social media listening to understand the lived experience of presbyopia: systematic search and content analysis study. J Med Internet Res. 2020;22: e18306.","journal-title":"J Med Internet Res"},{"key":"2432_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2265","volume":"340","author":"MJ Haran","year":"2010","unstructured":"Haran MJ, Cameron ID, Ivers RQ, Simpson JM, Lee BB, Tanzer M, et al. Effect on falls of providing single lens distance vision glasses to multifocal glasses wearers: VISIBLE randomised controlled trial. The BMJ. 2010;340: c2265.","journal-title":"The BMJ"},{"key":"2432_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/opo.12091","volume":"34","author":"WN Charman","year":"2014","unstructured":"Charman WN. Developments in the correction of presbyopia I: spectacle and contact lenses. Ophthalmic Physiol Opt. 2014;34:8\u201329.","journal-title":"Ophthalmic Physiol Opt"},{"key":"2432_CR12","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.2147\/OPTH.S259011","volume":"15","author":"JA Katz","year":"2021","unstructured":"Katz JA, Karpecki PM, Dorca A, Chiva-Razavi S, Floyd H, Barnes E, et al. Presbyopia - a review of current treatment options and emerging therapies. Clin Ophthalmol Auckl NZ. 2021;15:2167\u201378.","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"2432_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40662-016-0065-3","volume":"3","author":"A Abdelkader","year":"2016","unstructured":"Abdelkader A, Kaufman HE. Clinical outcomes of combined versus separate carbachol and brimonidine drops in correcting presbyopia. Eye Vis Lond Engl. 2016;3:31.","journal-title":"Eye Vis Lond Engl"},{"key":"2432_CR14","unstructured":"Abbvie News Center. U.S. Food and Drug Administration Approves VUITYTM (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision). 2021. https:\/\/news.abbvie.com\/news\/press-releases\/us-food-and-drug-administration-approves-vuity-pilocarpine-hci-ophthalmic-solution-125-first-and-only-eye-drop-to-treat-presbyopia-age-related-blurry-near-vision.htm. Accessed 4 May\u00a02022."},{"key":"2432_CR15","doi-asserted-by":"crossref","unstructured":"Korenfeld MS, Robertson SM, Stein JM, Evans DG, Rauchman SH, Sall KN, et al. Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial. Eye. 2021;35:3292\u2013301.","DOI":"10.1038\/s41433-020-01391-z"},{"key":"2432_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40900-021-00294-x","volume":"7","author":"D Feldman","year":"2021","unstructured":"Feldman D, Kruger P, Delbecque L, Duenas A, Bernard-Poenaru O, Wollenschneider S, et al. Co-creation of practical \u201chow-to guides\u201d for patient engagement in key phases of medicines development\u2014from theory to implementation. Res Involv Engagem. 2021;7:57.","journal-title":"Res Involv Engagem"},{"key":"2432_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/HJH.0000000000002592","volume":"39","author":"RE Schmieder","year":"2021","unstructured":"Schmieder RE, Kandzari DE, Wang T-D, Lee Y-H, Lazarus G, Pathak A. Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. J Hypertens. 2021;39:162\u20138.","journal-title":"J Hypertens"},{"key":"2432_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2019-000315","volume":"4","author":"P Asbell","year":"2019","unstructured":"Asbell P, Messmer E, Chan C, Johnson G, Sloesen B, Cook N. Defining the needs and preferences of patients with dry eye disease. BMJ Open Ophthalmol. 2019;4: e000315.","journal-title":"BMJ Open Ophthalmol"},{"key":"2432_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2019-000360","volume":"4","author":"E Messmer","year":"2019","unstructured":"Messmer E, Chan C, Asbell P, Johnson G, Sloesen B, Cook N. Comparing the needs and preferences of patients with moderate and severe dry eye symptoms across four countries. BMJ Open Ophthalmol. 2019;4: e000360.","journal-title":"BMJ Open Ophthalmol"},{"key":"2432_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40123-019-0188-4","volume":"8","author":"N Cook","year":"2019","unstructured":"Cook N, Mullins A, Gautam R, Medi S, Prince C, Tyagi N, et al. Evaluating patient experiences in dry eye disease through social media listening research. Ophthalmol Ther. 2019;8:407\u201320.","journal-title":"Ophthalmol Ther"},{"key":"2432_CR21","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.5805","volume":"18","author":"V Risson","year":"2016","unstructured":"Risson V, Ghodge B, Bonzani CI, Korn RJ, Medin J, Saraykar T, et al. Linked patient-reported outcomes data from patients with multiple sclerosis recruited on an open internet platform to health care claims databases identifies a representative population for real-life data analysis in multiple sclerosis. J Med Internet Res. 2016;18: e249.","journal-title":"J Med Internet Res"},{"key":"2432_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2017.06.033","volume":"182","author":"KF Farrand","year":"2017","unstructured":"Farrand KF, Fridman M, Stillman I\u00d6, Schaumberg DA. Prevalence of diagnosed dry eye disease in the united states among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90\u20138.","journal-title":"Am J Ophthalmol"},{"issue":"121","key":"2432_CR23","first-page":"1577","volume":"2003","author":"PJ McDonnell","year":"1960","unstructured":"McDonnell PJ, Lee P, Spritzer K, Lindblad AS, Hays RD. Associations of presbyopia with vision-targeted health-related quality of life. Arch Ophthalmol Chic Ill. 1960;2003(121):1577\u201381.","journal-title":"Arch Ophthalmol Chic Ill"},{"issue":"4","key":"2432_CR24","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40123-021-00391-w","volume":"10","author":"N Johnson","year":"2021","unstructured":"Johnson N, Shirneshan E, Coon CD, Stokes J, Wells T, Lundy JJ, et al. Development of the presbyopia impact and coping questionnaire. Ophthalmol Ther. 2021;10(4):1057\u201375.","journal-title":"Ophthalmol Ther."},{"key":"2432_CR25","unstructured":"Donders FC, Moore WD. On the Anomalies of Accommodation and Refraction of the Eye: With a Preliminary Essay on Physiological Dioptrics. New Sydenham society; 1864. https:\/\/books.google.se\/books?id=d3ToAAAAIAAJ."},{"key":"2432_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12603-012-0059-3","volume":"16","author":"Y Uchino","year":"2012","unstructured":"Uchino Y, Uchino M, Dogru M, Fukagawa K, Tsubota K. Improvement of accommodation with anti-oxidant supplementation in visual display terminal users. J Nutr Health Aging. 2012;16:478\u201381.","journal-title":"J Nutr Health Aging"},{"key":"2432_CR27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.ophtha.2004.12.040","volume":"112","author":"Y Takahashi","year":"2005","unstructured":"Takahashi Y, Igaki M, Suzuki A, Takahashi G, Dogru M, Tsubota K. The effect of periocular warming on accommodation. Ophthalmology. 2005;112:1113\u20138.","journal-title":"Ophthalmology"},{"key":"2432_CR28","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1038\/s41598-021-81748-w","volume":"11","author":"H Nagashima","year":"2021","unstructured":"Nagashima H, Sasaki N, Amano S, Nakamura S, Hayano M, Tsubota K. Oral administration of resveratrol or lactic acid bacterium improves lens elasticity. Sci Rep. 2021;11:2174.","journal-title":"Sci Rep"},{"key":"2432_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.pec.2014.06.014","volume":"96","author":"F L\u00e9gar\u00e9","year":"2014","unstructured":"L\u00e9gar\u00e9 F, Thompson-Leduc P. Twelve myths about shared decision making. Patient Educ Couns. 2014;96:281\u20136.","journal-title":"Patient Educ Couns"},{"key":"2432_CR30","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2003.08.021","volume":"110","author":"S Berry","year":"2003","unstructured":"Berry S, Mangione CM, Lindblad AS, McDonnell PJ. Development of the National Eye Institute refractive error correction quality of life questionnaire: focus groups. Ophthalmology. 2003;110:2285\u201391.","journal-title":"Ophthalmology"},{"key":"2432_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jcrs.2011.07.032","volume":"38","author":"PJ Buckhurst","year":"2012","unstructured":"Buckhurst PJ, Wolffsohn JS, Gupta N, Naroo SA, Davies LN, Shah S. Development of a questionnaire to assess the relative subjective benefits of presbyopia correction. J Cataract Refract Surg. 2012;38:74\u20139.","journal-title":"J Cataract Refract Surg"},{"key":"2432_CR32","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jcrs.2009.11.019","volume":"36","author":"K Pesudovs","year":"2010","unstructured":"Pesudovs K, Gothwal VK, Wright T, Lamoureux EL. Remediating serious flaws in the National Eye Institute Visual Function Questionnaire. J Cataract Refract Surg. 2010;36:718\u201332.","journal-title":"J Cataract Refract Surg"},{"key":"2432_CR33","doi-asserted-by":"publisher","first-page":"5685","DOI":"10.1167\/iovs.10-67951","volume":"52","author":"C McAlinden","year":"2011","unstructured":"McAlinden C, Skiadaresi E, Moore J, Pesudovs K. Subscale assessment of the NEI-RQL-42 questionnaire with Rasch analysis. Invest Ophthalmol Vis Sci. 2011;52:5685\u201394.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02432-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02432-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02432-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T13:05:36Z","timestamp":1651755936000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02432-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2432"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02432-9","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]},"assertion":[{"value":"9 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a non-interventional study. All methods were carried out in accordance with relevant guidelines and regulations. Approval of all experimental protocols by institutional and\/or licensing committee was not sought as the project falls under Office for Human Research Protections (OHRP) Exempt Categories 45 CFR 46.101(B) i.e., research involving the use of educational tests (cognitive, diagnostic, aptitude, achievement), survey procedures, interview procedures or observation of public behaviour (). Further, members of the roundtable were informed of their involvement in research activities via the user agreement and privacy policy before participating in the virtual discussion. All participants provided informed consent to participate and to publish the outcomes of the discussion. Anonymity and adequate protection of participants\u2019 personal data was ensured. The virtual roundtable discussion was conducted on a secure website, with all information protected from external sources. All posts were anonymised for the purpose of publication. In this report, the use of \u2018participant\u2019 refers to the feedback provided without attribution to any named individual.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MB reports speaker or advisory board honoraria or research support from ABB Optical, Alcon Laboratories, Allergan, Art Optical, Bausch\u2009+\u2009Lomb Health, Contamac, CooperVision, CSEye, Horizon Therapeutics, Johnson & Johnson Vision Care, Kala, Lenstech, Novartis, Optovue, Oyster Point, RVL, Sun Pharma, Tarsus, Tangible Science, Thea, Santen, Walman Optical and Zea Vision. JT is President and CEO of Prevent Blindness, an organisation which has received support from Novartis in the past for projects unrelated to the current work. EB, MW and FP are employees of Novartis; JA and PK report no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"204"}}